Glabridin
CAS 59870-68-7
Glabridin (CAS 59870-68-7) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 45.29017857142857 ug.mL-1 | 28 | - |
| - | Potency | 20293.416666666668 nM | 12 | - |
| - | IC50 | 27912.85714285714 nM | 6 | - |
| - | AC50 | 6662.5 nM | 2 | - |
| - | Ki | 7000 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| GLABRIDIN | 1603522 | SU | MTHSPL |
| glabridin | 1603522 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Glabridin used for in pharmaceutical contexts?
Glabridin (CAS 59870-68-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Glabridin?
No adverse-event association or SIDER side-effect rows are rendered for Glabridin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Glabridin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Glabridin with EU status "permitted".
What clinical phase is Glabridin in?
No phase 1-4 clinical development badge is rendered for Glabridin because the matched compound identifier rows do not contain a max-phase value.